These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33941739)

  • 21. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR; Bhatt J
    Cochrane Database Syst Rev; 2012 Feb; (2):CD002009. PubMed ID: 22336782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis.
    Bates RD; Nahata MC; Jones JW; McCoy K; Young G; Cox S; Barson WJ
    Chest; 1997 Nov; 112(5):1208-13. PubMed ID: 9367459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
    Madsen V; Lind A; Rasmussen M; Coulthard K
    J Cyst Fibros; 2004 Dec; 3(4):249-51. PubMed ID: 15698943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there a multinational consensus of tobramycin prescribing and monitoring for cystic fibrosis? Survey of current therapeutic drug monitoring practices in USA/Canada, UK/Ireland, and Australia/New Zealand.
    Larcombe R; Coulthard K; Eaton V; Tai A; Reuter S; Ward M
    Eur J Hosp Pharm; 2024 Jun; 31(4):301-306. PubMed ID: 36600520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
    Smyth AR; Bhatt J
    Cochrane Database Syst Rev; 2010 Jan; (1):CD002009. PubMed ID: 20091528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
    Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
    J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalized tobramycin dosing in children with cystic fibrosis: a comparative clinical evaluation of log-linear and Bayesian methods.
    Imani S; Fitzgerald DA; Robinson PD; Selvadurai H; Sandaradura I; Lai T
    J Antimicrob Chemother; 2022 Nov; 77(12):3358-3366. PubMed ID: 36172897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin.
    Ruddy J; Emerson J; Moss R; Genatossio A; McNamara S; Burns JL; Anderson G; Rosenfeld M
    J Aerosol Med Pulm Drug Deliv; 2013 Apr; 26(2):69-75. PubMed ID: 22620494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
    van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
    J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the predictive value of area under the curve versus maximum serum concentration of intravenous tobramycin in cystic fibrosis patients treated for an acute pulmonary exacerbation.
    Landmesser KB; Autry EB; Gardner BM; Bosko KA; Schadler A; Kuhn RJ
    Pediatr Pulmonol; 2021 Oct; 56(10):3209-3216. PubMed ID: 34241975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.
    Stenbit AE; Bullington WM; Heh JL; Flume PA
    J Cyst Fibros; 2013 Jul; 12(4):403-6. PubMed ID: 23266092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Individualized Delivery of Vancomycin by Model-Informed Bayesian Dosing Approach to Maintain an AUC24 Target in Critically Ill Patients.
    Rao Z; Guo SM; Wei YM
    Chemotherapy; 2024; 69(1):49-55. PubMed ID: 37591210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.
    Aminimanizani A; Beringer PM; Kang J; Tsang L; Jelliffe RW; Shapiro BJ
    J Antimicrob Chemother; 2002 Oct; 50(4):553-9. PubMed ID: 12356801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm.
    Touw DJ; Vinks AA; Neef C
    Pharm World Sci; 1997 Jun; 19(3):142-51. PubMed ID: 9259030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tobramycin pharmacokinetics in patients with cystic fibrosis preceding and following lung transplantation.
    Dupuis RE; Sredzienski ES
    Ther Drug Monit; 1999 Apr; 21(2):161-5. PubMed ID: 10217334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
    Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
    Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation.
    Peris-Marti JF; Borras-Blasco J; Rosique-Robles JD; Gonzalez-Delgado M
    J Clin Pharm Ther; 2004 Feb; 29(1):65-70. PubMed ID: 14748900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis?
    van Maarseveen EM; van der Meer R; Neef C; Heijerman HGM; Touw DJ
    Ther Drug Monit; 2020 Aug; 42(4):595-599. PubMed ID: 32049889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?
    Crass RL; Pai MP; Lodise TP
    J Antimicrob Chemother; 2019 Jan; 74(1):126-129. PubMed ID: 30252050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
    Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
    Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.